Prochymal for Pediatric Patients with End-Stage Acute GvHD

Enrollment for this trial has been completed.
The objective of this study was to evaluate the safety and efficacy of Prochymal in those pediatric patients with end-stage refractory acute GvHD.   Patients in this trial were treated with Prochymal every 72 hours as needed for a response, for a maximum of eight treatments.

Trial Overview

A patient was eligible if he or she was between the ages of 6 months and 17 years, had previously received an allogeneic hemopoietic stem cell transplant (i.e. bone marrow, cord blood, or peripheral blood), and had developed acute GvHD resistant to multiple standard therapies.

Trial Highlights

• 100% (12/12) end-stage pediatric patients responded to treatment with Prochymal
• 58% (7/12) of patients experienced a complete resolution of GvHD
• Prochymal is well-tolerated

Click here to read more about the pediatric treatment refractory GvHD trial results.

Click here to view the poster presented at the 2007 American Society of Hematology Meeting.